This study determines whether 70-gene signature assay findings are associated with physicians’ adjuvant treatment recommendations among patients with early breast cancer.
This biomarker study examines the efficacy of irinotecan plus panitumumab in patients with advanced colorectal cancer whose tumors had high HER3 messenger RNA expression.
A woman in her 80s with a history of recurrent oral cancer was diagnosed with squamous cell carcinoma located at the margin of a palatal graft; surveillance imaging reveals metabolic activity in her left vocal cord. What is your diagnosis?
This study evaluates the natural history of von Hippel–Lindau disease–associated pancreatic lesions to determine the factors associated with pancreatic neuroendocrine tumor phenotype and prognosis.
This Viewpoint examines consideration of human epidermal growth factor receptor 2 as a biomarker in metastatic CRC.
This cohort study assesses the association of locoregional surgery at diagnosis for small intestine neuroendocrine tumors with survival among Swedish patients.
This cross-sectional survey study quantifies the prevalence of self-reported “job lock” in a sample of full-time employed childhood cancer survivors and their siblings participating in the Childhood Cancer Survivor Study.
This analysis uses SEER Medicaid data to quantify changes in health insurance coverage under the Affordable Care Act among nonelderly patients newly diagnosed with cancer.
This cohort study examines the prognostic role of CD8+ T lymphocytes for survival among women with epithelial ovarian cancer.
This study compared response to ketoconazole treatment among patients with castration-resistant prostate cancer who had 0, 1, or 2 HSD3B1 variant alleles.
This cohort study evaluates whether the HSD3B1 (1245C) allele is associated with worse clinical outcomes from androgen-deprivation therapy for biochemical recurrence after radiotherapy.
This data analysis of the Global Burden of Disease 2015 study on primary liver cancer reports incidence, mortality, and disability-adjusted life-years for 195 countries or territories from 1990 to 2015, and presents global, regional, and national estimates on the burden of liver cancer.
This pooled analysis of 2 randomized clinical trials evaluates the association of DNA mismatch repair status with disease-free survival in patients with stage III colon cancer treated with FOLFOX.